Supplementary Data 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma | Synapse
September 13, 2024
Supplementary Data 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Individual whole slide images of HNSCC PDX tumor used for TME analysis.